Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $132.45B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.95. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| BMY | TMF | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $44.14 |
52-Week Low | $42.60 | $30.59 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $31.43 with a modest 0.67% daily gain. Technical indicators show a bearish bias overall, with moving averages signaling caution, though oscillators are neutral. The ETF, which provides 3x leveraged exposure to long-duration U.S. Treasuries, faces significant volatility due to its daily leverage reset mechanism. Recent news highlights its high-risk nature, with one article noting a substantial decline from a $10,000 investment five years ago to approximately $1,527, underscoring the perils of long-term holding.
The outlook for TMF is highly speculative and tied to interest rate movements. While some see opportunity at perceived lows in the bond market, the consensus warns it is unsuitable for long-term investment. Primary risks include extreme volatility from daily leverage resets and adverse shifts in Treasury yields. It remains a tactical, short-term instrument for experienced traders, not a core portfolio holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
